<DOC>
	<DOCNO>NCT00686803</DOCNO>
	<brief_summary>The objective study evaluate safety , tolerability , pharmacokinetics subcutaneous ( SC ) PL-3994 , relative placebo subject control hypertension . Including evaluation effect PL3994 blood pressure .</brief_summary>
	<brief_title>Safety Study Subcutaneously Administered PL-3994 Subjects With Controlled Hypertension</brief_title>
	<detailed_description>Uncontrolled hypertension , include hypertensive urgency hypertensive emergency , commonly see emergency room urgent care setting . Current standard care include intravenously administer drug , difficult titrate require ongoing monitoring . This study examine effect PL-3994 patient control hypertension receive antihypertensive medication .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Subjects must diagnosis essential hypertension least 1 year , per subject verbal history Subject must stable dose least one , 3 antihypertensive medication least 3 month , per subject verbal history . Subject must systolic blood pressure screen 100 150 mmHg , diastolic blood pressure must exceed 105 mmHg . Subject weight great 100 kg less 50 kg . Any significant medical condition abnormal safety laboratory result , judgement Investigator would place subject significant risk .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>hypertension</keyword>
	<keyword>control hypertension</keyword>
	<keyword>hypertensive</keyword>
</DOC>